Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Epilepsy × TAS-119 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 1 Epilepsy 1 Advanced Solid Tumors 1

Interventions

LY3295668 erbumine 3 Topotecan 1 TAS-119 1 Paclitaxel 1 Midazolam 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02134067 2024-09-05

Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors

Taiho Oncology, Inc.

Phase 1 Terminated

Epilepsy, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡